Literature DB >> 18180343

Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.

J Tarning1, E A Ashley, N Lindegardh, K Stepniewska, L Phaiphun, N P J Day, R McGready, M Ashton, F Nosten, N J White.   

Abstract

The population pharmacokinetics of piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria treated with two different dosage regimens of dihydroartemisinin-piperaquine were characterized. Piperaquine pharmacokinetics in 98 Burmese and Karen patients aged 3 to 55 years were described by a two-compartment disposition model with first-order absorption and interindividual random variability on all parameters and were similar with the three- and four-dose regimens. Children had a lower body weight-normalized oral clearance than adults, resulting in longer terminal elimination half-lives and higher total exposure to piperaquine (area under the concentration-time curve from 0 to 63 days [AUC day 0-63]). However, children had lower plasma concentrations in the therapeutically relevant posttreatment prophylactic period (AUC day 3-20) because of smaller body weight-normalized central volumes of distribution and shorter distribution half-lives. Our data lend further support to a simplified once-daily treatment regimen to improve treatment adherence and efficacy and indicate that weight-adjusted piperaquine doses in children may need to be higher than in adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180343      PMCID: PMC2258541          DOI: 10.1128/AAC.00955-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Delaying antimalarial drug resistance with combination chemotherapy.

Authors:  N J White
Journal:  Parassitologia       Date:  1999-09

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

4.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

5.  Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects.

Authors:  Daniel Röshammar; Trinh Ngoc Hai; Sofia Friberg Hietala; Nguyen Van Huong; Michael Ashton
Journal:  Eur J Clin Pharmacol       Date:  2006-03-29       Impact factor: 2.953

6.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Authors:  A Ratcliff; H Siswantoro; E Kenangalem; R Maristela; R M Wuwung; F Laihad; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

8.  Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature.

Authors:  Gary Ginsberg; Dale Hattis; Babasaheb Sonawane; Abel Russ; Prerna Banati; Mary Kozlak; Susan Smolenski; Rob Goble
Journal:  Toxicol Sci       Date:  2002-04       Impact factor: 4.849

9.  Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.

Authors:  A R Hasugian; H L E Purba; E Kenangalem; R M Wuwung; E P Ebsworth; R Maristela; P M P Penttinen; F Laihad; N M Anstey; E Tjitra; R N Price
Journal:  Clin Infect Dis       Date:  2007-03-05       Impact factor: 9.079

10.  Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

Authors:  R N Price; A R Hasugian; A Ratcliff; H Siswantoro; H L E Purba; E Kenangalem; N Lindegardh; P Penttinen; F Laihad; E P Ebsworth; N M Anstey; E Tjitra
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

View more
  71 in total

1.  Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.

Authors:  R Kajubi; L Huang; P Jagannathan; N Chamankhah; M Were; T Ruel; C A Koss; A Kakuru; N Mwebaza; M Kamya; D Havlir; G Dorsey; P J Rosenthal; F T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

2.  Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.

Authors:  Marcus J Rijken; Rose McGready; Aung Phae Phyo; Niklas Lindegardh; Joel Tarning; Natthapon Laochan; Hla Hla Than; Oh Mu; Aye Kyi Win; Pratap Singhasivanon; Nicholas White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

3.  Determinants of MDA impact and designing MDAs towards malaria elimination.

Authors:  Bo Gao; Sompob Saralamba; Yoel Lubell; Lisa J White; Arjen M Dondorp; Ricardo Aguas
Journal:  Elife       Date:  2020-04-15       Impact factor: 8.140

4.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.

Authors:  Rada M Savic; Prasanna Jagannathan; Richard Kajubi; Liusheng Huang; Nan Zhang; Moses Were; Abel Kakuru; Mary K Muhindo; Norah Mwebaza; Erika Wallender; Tamara D Clark; Bishop Opira; Moses Kamya; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Francesca T Aweeka
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

6.  Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Authors:  Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh
Journal:  J Infect Dis       Date:  2013-02-27       Impact factor: 5.226

7.  Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Nguyen Xuan Thanh; Bui Dai; Jason P Geue; Russell S Addison; Thomas Travers; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

8.  Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.

Authors:  Shereen Katrak; Anne Gasasira; Emmanuel Arinaitwe; Abel Kakuru; Humphrey Wanzira; Victor Bigira; Taylor G Sandison; Jaco Homsy; Jordan W Tappero; Moses R Kamya; Grant Dorsey
Journal:  Malar J       Date:  2009-11-30       Impact factor: 2.979

9.  Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.

Authors:  D M Kiboi; B N Irungu; B Langat; S Wittlin; R Brun; J Chollet; O Abiodun; J K Nganga; V C S Nyambati; G M Rukunga; A Bell; A Nzila
Journal:  Exp Parasitol       Date:  2009-03-24       Impact factor: 2.011

10.  Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.

Authors:  Julien Zwang; Elizabeth A Ashley; Corine Karema; Umberto D'Alessandro; Frank Smithuis; Grant Dorsey; Bart Janssens; Mayfong Mayxay; Paul Newton; Pratap Singhasivanon; Kasia Stepniewska; Nicholas J White; François Nosten
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.